The clinical-stage biotech delivered positive trial results for its new COVID-19 preventative antibody treatment.
Harrow Health's (HROW) first-quarter top line is likely to have been driven by its recent product launches.
Catalent's (CTLT) Q3 results are likely to have been driven by robust segmental performances.
Revvity's (PKI) first-quarter results are likely to reflect weak performance at the Diagnostics segment, partially offset by strong demand for Life Sciences and Diagnostics franchise.
Invivyd, Inc. (IVVD) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates...
Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Invivyd, Inc. f/k/a Adagio Therapeutics, Inc. (“Invivyd” or the “Company”)...
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Invivyd, Inc. (f/k/a Adagio Therapeutics, Inc.) ("Adagio" or the "Company")...
/PRNewswire/ -- Attention Invivyd, Inc. f/k/a Adagio Therapeutics, Inc. ("Invivyd") (NASDAQ: IVVD) shareholders: The Law Offices of Vincent Wong announce that...
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, reminds investors that a class action lawsuit has been filed against Invivyd, Inc. (“Invivyd” or the “Company”)...
Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until April 3, 2023 to file lead plaintiff applications...